©2017 BY ADAPTVAC.

MANAGEMENT TEAM

 

WIAN DE JONGH

CEO
Board member

Dr. de Jongh (South African) has a M.Sc. in Chemical Engineering from the University of Stellenbosch, South Africa and was awarded a doctorate in Biotechnology from the Technical University of Denmark (DTU). Furthermore, Dr. de Jongh was awarded an affiliated associate professorship at DTU in 2017. Dr. de Jongh has 10 years experience in the Biopharmaceutical industry, 6 years as CSO of ExpreS2ion Biotechnologies. Dr. de Jongh is also CSO and co-founder of NASDAQ First North listed ExpreS2ion Biotechnologies.

ADAM SANDER

CSO
Board member

Associate Professor Adam Sander has a M.Sc.  in medical parasitology and holds a Ph.D. in molecular medicin at University of Copenhagen. Dr. Sander has expertise in protein engineering, vaccinology and molecular biology and is heading a research team working with development of vaccine delivery platforms. Dr. Sander is main inventor of the split-protein VLP vaccine platform, which forms the basis of AdaptVac’s proprietary technology. Dr. Sander is a co-founder of NextGen Vaccines.

BOARD MEMBERS

STEEN KLYSNER

Chairman of the Board

Dr. Klysner has + 25 years of experience from Biotech and Biopharmaceutical industry. This include ALK, Novo Nordisk, Pharmexa and Nordic Vaccine and most recently heading preclinical R&D and Quality at Allergopharma, the Allergy business unit of Merck KGaA (Germany). His expertise is focused on development, management commercialisation of innovative projects and businesses. He holds a M.Sc from University of Copenhagen, followed by a Ph.D. from the Danish Technical University and an Industrial Research degree from the Danish Academy of Technical sciences. Dr. Klysner is currently the CEO of ExpreS2ion Biotechnologies, a NASDAQ First North listed company.

PROF. ALI SALANTI

Board Member

Dr. Ali Salanti (AS) is founder and CEO of VAR2 Pharmaceuticals. He holds a Ph.D. in medicine and is Professor at University of Copenhagen. AS has a strong background in molecular biology and translational medicine, and he is currently running a clinical development program for a malaria vaccine. He received an ERC consolidator grant in 2014. Dr. Salanti is a co-founder of VAR2 Pharmaceuticals, VarCT Diagnostics, and NextGen Vaccines.

MORTEN NIELSEN

Board Member

Dr. Nielsen is a Associate Professor at Copenhagen University and has hands on expertise in process design within CMC as well as Toxicity, Stability and Potency testing. Furthermore, he has been involved in the shaping and writing clinical protocol, the Investigators Brochure and IMPD, as well as participated in writing of the clinical protocol for two clinical trials.  Associate Professor Morten A Nielsen is a co-founder of VAR2 Pharmaceuticals, VarCT Diagnostics, and NextGen Vaccines.

BENT FRANDSEN

Board Member

Bent Frandsen has 23 years of professional experience in management, finance, and business development positions in multinational companies, including 19 years Life Science experience at public listed companies, Lundbeck, ALK-Abelló, Coloplast, and private companies, NsGene, CMC Biologics, and Amphidex. Bent has completed licensing, services, M&A, and new cash deals in excess of €200 million, and has furthermore been in charge of successfully closing numerous collaboration agreements pertaining to research and development of both new chemical entities and biologicals. Bent graduated as M.Sc. in Finance and Strategic Planning from Copenhagen Business School, Denmark, in 1993. Bent is currently VP Business Development for ExpreS2ion Biotechnologies.

 

WIAN DE JONGH

CEO
Board member

Dr. de Jongh (South African) has a M.Sc. in Chemical Engineering from the University of Stellenbosch, South Africa and was awarded a doctorate in Biotechnology from the Technical University of Denmark (DTU). Furthermore, Dr. de Jongh was awarded an affiliated associate professorship at DTU in 2017. Dr. de Jongh has 10 years experience in the Biopharmaceutical industry, 6 years as CSO of ExpreS2ion Biotechnologies. Dr. de Jongh is also CSO and co-founder of NASDAQ First North listed ExpreS2ion Biotechnologies.

ADAM SANDER

CSO
Board member

Associate Professor Adam Sander has a M.Sc.  in medical parasitology and holds a Ph.D. in molecular medicin at University of Copenhagen. Dr. Sander has expertise in protein engineering, vaccinology and molecular biology and is heading a research team working with development of vaccine delivery platforms. Dr. Sander is main inventor of the split-protein VLP vaccine platform, which forms the basis of AdaptVac’s proprietary technology. Dr. Sander is a co-founder of NextGen Vaccines.